Charles River Laboratories (NYSE: CRL) reported Q2 EPS of $1.58, $0.32 better than the analyst estimate of $1.26. Revenue for the quarter came in at $682.6 million versus the consensus estimate of $641.63 million.

GUIDANCE:

Charles River Laboratories sees FY2020 EPS of $7.05-$7.35, versus the consensus of $6.91.

• Revenue growth, reported 7.5% – 9.0%

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.